# MyRisk Hereditary Cancer (Myriad Genetics)

Source: https://onco.cc/drugs/myriad-myrisk/  
OnCo record `myriad-myrisk` (Test). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Myriad's multi-gene blood test for inherited cancer risk, covering 63 genes including BRCA1, BRCA2 and the Lynch syndrome genes, ordered through a clinician.

## Summary

Registered in the NIH Genetic Testing Registry as GTR000603556.3 (version updated 15 December 2025) by Myriad Genetics, Inc. (Utah, CLIA 05D2299797 and 46D2275645): next-generation sequencing of 63 genes, among them BRCA1, BRCA2, PALB2, ATM, CHEK2, the Lynch genes, APC, MUTYH, CDH1, CTNNA1, STK11, TP53, PTEN, CDKN2A, FLCN, VHL, the SDH genes and HOXB13. GTR records it as a test developed by the laboratory; it is not among the FDA-authorised hereditary cancer products (openFDA product codes QAZ and QVU and PMA product code PJG, searched 4 November 2026). Myriad's FDA-approved companion diagnostic for germline BRCA is a separate test, BRACAnalysis CDx.

## Fields

- Kind: Test
- Status: established
- Last checked: 2026-11-04
- Also known as: myRisk; myRisk Hereditary Cancer; Myriad myRisk
- Tags: test; hereditary
- Brand: MyRisk
- Modality: Germline hereditary cancer sequencing panel (laboratory-developed test)
- Mechanism: Next-generation sequencing of germline DNA across 63 genes, registered in the Genetic Testing Registry as a test developed by the laboratory.

## Sources

- NIH Genetic Testing Registry GTR000603556.3: https://www.ncbi.nlm.nih.gov/gtr/tests/603556/
- NIH Genetic Testing Registry data file (test_version.gz): https://ftp.ncbi.nlm.nih.gov/pub/GTR/data/test_version.gz

## Connected records

- drugs: [BRACAnalysis CDx](https://onco.cc/drugs/bracanalysis-cdx/)
- technologies: [Germline (hereditary) testing](https://onco.cc/technologies/germline-testing/)
- targets: [ATM](https://onco.cc/targets/atm/), [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [CDH1](https://onco.cc/targets/cdh1/), [CHEK2](https://onco.cc/targets/chek2/), [MLH1](https://onco.cc/targets/mlh1/), [MSH2](https://onco.cc/targets/msh2/), [PALB2](https://onco.cc/targets/palb2/), [TP53](https://onco.cc/targets/tp53/)
- companies: [Myriad Genetics](https://onco.cc/companies/myriad-genetics/)
- terms: [Birt-Hogg-Dubé syndrome](https://onco.cc/terms/birt-hogg-dube-syndrome/), [Familial atypical multiple mole melanoma syndrome (familial melanoma)](https://onco.cc/terms/familial-atypical-multiple-mole-melanoma/), [Hereditary cancer syndromes](https://onco.cc/terms/hereditary-cancer-syndromes/), [Hereditary diffuse gastric cancer](https://onco.cc/terms/hereditary-diffuse-gastric-cancer/), [Lynch syndrome](https://onco.cc/terms/lynch-syndrome/)

---
JSON: https://onco.cc/api/v1/entities/myriad-myrisk.json